12 research outputs found
Chronobiology of high blood pressure
BIOCOS, the project aimed at studying BIOlogical systems in their COSmos, has obtained
a great deal of expertise in the fields of blood pressure (BP) and heart rate (HR) monitoring and of
marker rhythmometry for the purposes of screening, diagnosis, treatment, and prognosis. Prolonging
the monitoring reduces the uncertainty in the estimation of circadian parameters; the current
recommendation of BIOCOS requires monitoring for at least 7 days. The BIOCOS approach consists
of a parametric and a non-parametric analysis of the data, in which the results from the individual
subject are being compared with gender- and age-specified reference values in health.
Chronobiological designs can offer important new information regarding the optimization of
treatment by timing its administration as a function of circadian and other rhythms.
New technological developments are needed to close the loop between the monitoring of blood
pressure and the administration of antihypertensive drugs
The relationship between glycaemic variability and cardiovascular autonomic dysfunction in patients with type 1 diabetes: A systematic review
Cytotoxic Activities of Several Geranyl-Substituted Flavanones
Nine geranylated flavanones isolated from the fruits of Paulownia tomentosa (4-12) and two from the roots of Morus alba (13 and
14) were examined for cytotoxicity to selected human cancer cell lines and normal human fibroblasts. Cytotoxicity was determined
in vitro using a calcein AM cytotoxicity assay. Cytotoxicity for the THP-1 monocytic leukemia cell line was tested using erythrosin
B cell staining. The geranylated compounds tested were compared with the known simple flavanone standards taxifolin (1), naringenin
(2), and hesperetin (3) and with the standard anticancer drugs olomoucine II, diaziquone, and oxaliplatin and the antineoplastic
compound camptothecin, and showed different levels of cytotoxicity. The effects of structural changes on cytotoxic activity, including
geranyl substitution of the flavanone skeleton and the oxidation pattern of ring B of the flavanones, are discussed
Analysis of diagonals in cross recurrence plots between heart rate and systolic blood pressure during supine position and active standing in healthy adults
Changes in Risk Factors and Exercise Capacity After Cardiac Rehabilitation and Its Effect on Hospital Readmission
Arabidopsis ABCG14 protein controls the acropetal translocation of root-synthesized cytokinins
Over-Expressed Testis-Specific Protein Y-Encoded 1 as a Novel Biomarker for Male Hepatocellular Carcinoma
Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2)
Objective: To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of 10 and 15 µg bimatoprost implant in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). Methods: This randomized, 20-month, multicenter, masked, parallel-group, phase 3 trial enrolled 528 patients with OAG or OHT and an open iridocorneal angle inferiorly in the study eye. Study eyes were administered 10 or 15 µg bimatoprost implant on day 1, week 16, and week 32, or twice-daily topical timolol maleate 0.5%. Primary endpoints were IOP and IOP change from baseline through week 12. Safety measures included treatment-emergent adverse events (TEAEs) and corneal endothelial cell density (CECD). Results: Both 10 and 15 µg bimatoprost implant met the primary endpoint of noninferiority to timolol in IOP lowering through 12 weeks. Mean IOP reductions from baseline ranged from 6.2–7.4, 6.5–7.8, and 6.1–6.7 mmHg through week 12 in the 10 µg implant, 15 µg implant, and timolol groups, respectively. IOP lowering was similar after the second and third implant administrations. Probabilities of requiring no IOP-lowering treatment for 1 year after the third administration were 77.5% (10 µg implant) and 79.0% (15 µg implant). The most common TEAE was conjunctival hyperemia, typically temporally associated with the administration procedure. Corneal TEAEs of interest (primarily corneal endothelial cell loss, corneal edema, and corneal touch) were more frequent with the 15 than the 10 µg implant and generally were reported after repeated administrations. Loss in mean CECD from baseline to month 20 was ~ 5% in 10 µg implant-treated eyes and ~ 1% in topical timolol-treated eyes. Visual field progression (change in the mean deviation from baseline) was reduced in the 10 µg implant group compared with the timolol group. Conclusions: The results corroborated the previous phase 3 study of the bimatoprost implant. The bimatoprost implant met the primary endpoint and effectively lowered IOP. The majority of patients required no additional treatment for 12 months after the third administration. The benefit-risk assessment favored the 10 over the 15 µg implant. Studies evaluating other administration regimens with reduced risk of corneal events are ongoing. The bimatoprost implant has the potential to improve adherence and reduce treatment burden in glaucoma. Clinicaltrials.gov Identifier: NCT02250651